openPR Logo
Press release

HER2 negative Breast Cancer Pipeline and Companies Analysis Report (2022): Analysis of Clinical Trials Landscape, Therapies, Route of Administration, Mechanism of Action and Developments | DelveInsight

10-21-2022 10:08 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

HER2 negative Breast Cancer Pipeline

HER2 negative Breast Cancer Pipeline

HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously working towards developing 85+ HER2 negative Breast Cancer treatment therapies, as per DelveInsight

DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.

Click here to know more about the HER2 negative Breast Cancer Pipeline report offerings: https://www.delveinsight.com/report-store/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with 85+ active players working to develop 85+ pipeline treatment therapies.
• Some of the key pharmaceutical companies working to develop potential drug candidates to improve the HER2 negative Breast Cancer treatment scenario include BeiGene, Olema Pharmaceuticals, AstraZeneca, Radius Health, Adagene Inc, H3 Biomedicine Inc., Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, InventisBio Co., Ltd, Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai Co., Ltd., Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Eli Lilly and Company, Laekna Limited, Sermonix Pharmaceuticals Inc., Modra Pharmaceuticals, MedImmune LLC, QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer, Merus N.V., Seagen, Relay Therapeutics, Inc., Blueprint Medicines Corporation, TransThera Sciences (Nanjing), Inc., HUTCHMED, VelosBio Inc., Dantari, Inc., GlaxoSmithKline, G1 Therapeutics, Inc., Spectrum Pharmaceuticals, Inc, Taizhou EOC Pharma Co., Ltd., Xuanzhu Biopharmaceutical Co., Ltd., Regor Pharmaceuticals Inc, Astex Pharmaceuticals, Inc., Kind Pharmaceuticals LLC, Genor Biopharma Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., Nerviano Medical Sciences, Tolmar Inc., Zeno Alpha Inc., Accutar Biotechnology Inc, Jiangsu Hansoh Pharmaceutical Co., Ltd., Zenith Epigenetics, Cantargia, BioLite, Inc., PharmAbcine, Ayala Pharmaceuticals, Inc., ERYtech Pharma, SynCore Biotechnology Co., Ltd., Phoenix Molecular Designs, Chipscreen Biosciences, Ltd., OncoTherapy Science, Inc., OncoPep, Inc., and many others.
• Essential HER2 negative Breast Cancer pipeline therapies such as BGB-290, OP-1250, AZD9833, Elacestrant, ADG106, H3B-6545, Dato-DXd, HRS8807, TAVO, Mitoxantrone Hydrochloride, Gedatolisib, D-0502, Ipatasertib, ANG1005, Nivolumab, Ipilimumab, Lenvatinib, Onapristone, Xentuzumab, CX-2009, BPI-1178, LY3484356, Afuresertib, Lasofoxifene, ModraDoc006/r, MEDI4736, Infigratinib, SM-88, PQR309, PF-07248144, MCLA-128, SGN-CD228A, RLY-2608, BLU-222, TT-00420, HMPL-013, Zilovertamab vedotin, DAN-222, Niraparib, G1T38, Poziotinib Hydrochloride, EOC202, XZP-3287, RGT-419B, ASTX727, AND019, Lerociclib, SGN-STNV, SCR-6852, NMS-03305293, TOL2506, ZN-c5, AC682, HS-10342, ZEN003694, Nadunolimab, BLEX 404, Olinvacimab, AL101, eryaspase, EndoTAG-1, PMD-026, Chiauranib, OTS167PO, PVX-410, and others are under development in different phases of clinical trials.
• In January 2022, Celcuity announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to the Company's lead drug candidate, gedatolisib, for the treatment of patients with HR+/HER2- metastatic breast cancer after progression on CDK4/6 therapy.
• In December 2021, H3 Biomedicine Inc. (H3), announced the presentation of two posters at the 2021 San Antonio Breast Cancer Symposium (SABCS) being held in a hybrid format on December 7- 10, 2021. The presentations include interim investigational data from H3's ongoing clinical development program, H3B-6545, a potential first-in-class, orally available Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer.
• The investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly decreased the risk of death or disease progression and increased progression-free survival compared with standard-of-care endocrine therapy for postmenopausal patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancers that progressed on prior endocrine and targeted therapies, according to results from the phase III EMERALD trial, which were presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.
• In November 2021, Olema Pharmaceuticals, Inc. announced the first clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) in development for the treatment of metastatic breast cancer and other women's cancers.

Request a sample and discover more about the HER2 negative Breast Cancer Emerging Therapies @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The HER2 negative Breast Cancer pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage HER2 negative Breast Cancer products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the HER2 negative Breast Cancer pipeline landscape.

HER2 negative Breast Cancer Overview
Most Breast Cancers express the Estrogen Receptor (ER) receptor and are negative for the human epidermal growth factor receptor 2 (HER2) receptor. ER+/ HER2 - ve Breast Cancer includes tumors that are ER-positive and PR positive, but negative for HER2. ER+/ HER2 - ve Breast Cancer is heterogeneous and accounts for about 70% of all breast cancers. HER2" stands for human epidermal growth factor receptor 2. There are various types of breast cancer, some have hormone receptors like estrogen or progesterone (some have both) and are called ER+ or PR+ breast cancer respectively.

Find out more about the disease and recent developments in HER2 negative Breast Cancer Pipeline landscape @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

HER2 negative Breast Cancer Therapeutics Assessment
The HER2 negative Breast Cancer Pipeline report proffers an integral view of the HER2 negative Breast Cancer emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Scope of the HER2 negative Breast Cancer Pipeline Report
• Coverage: Global
• Therapeutic Assessment By HER2 negative Breast Cancer Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By HER2 negative Breast Cancer Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
• Therapeutics Assessment By HER2 negative Breast Cancer Therapeutics Route of Administration: Oral, Intravenous, Inhalation, Subcutaneous
• Therapeutics Assessment By HER2 negative Breast Cancer Therapies Molecule Type: Gene therapy, Stem cell therapy, Small molecules
• Therapeutics Assessment By HER2 negative Breast Cancer Therapies Mechanism of Action: Selective estrogen receptor degrader, Estrogen receptor alpha antagonist, Phosphoinositide 3-kinase (PI3K) inhibitor, Selective estrogen receptor degraders
• Key HER2 negative Breast Cancer Companies: BeiGene, Olema Pharmaceuticals, AstraZeneca, Radius Health, Adagene Inc, H3 Biomedicine Inc., Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, InventisBio Co., Ltd, Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai Co., Ltd., Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Eli Lilly and Company, Laekna Limited, Sermonix Pharmaceuticals Inc., Modra Pharmaceuticals, MedImmune LLC, QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer, Merus N.V., Seagen, Relay Therapeutics, Inc., Blueprint Medicines Corporation, TransThera Sciences (Nanjing), Inc., HUTCHMED, VelosBio Inc., Dantari, Inc., GlaxoSmithKline, G1 Therapeutics, Inc., Spectrum Pharmaceuticals, Inc, Taizhou EOC Pharma Co., Ltd., Xuanzhu Biopharmaceutical Co., Ltd., Regor Pharmaceuticals Inc, Astex Pharmaceuticals, Inc., Kind Pharmaceuticals LLC, Genor Biopharma Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., Nerviano Medical Sciences, Tolmar Inc., Zeno Alpha Inc., Accutar Biotechnology Inc, Jiangsu Hansoh Pharmaceutical Co., Ltd., Zenith Epigenetics, Cantargia, BioLite, Inc., PharmAbcine, Ayala Pharmaceuticals, Inc., ERYtech Pharma, SynCore Biotechnology Co., Ltd., Phoenix Molecular Designs, Chipscreen Biosciences, Ltd., OncoTherapy Science, Inc., OncoPep, Inc., and many others.
• Key HER2 negative Breast Cancer Pipeline Therapies: BGB-290, OP-1250, AZD9833, Elacestrant, ADG106, H3B-6545, Dato-DXd, HRS8807, TAVO, Mitoxantrone Hydrochloride, Gedatolisib, D-0502, Ipatasertib, ANG1005, Nivolumab, Ipilimumab, Lenvatinib, Onapristone, Xentuzumab, CX-2009, BPI-1178, LY3484356, Afuresertib, Lasofoxifene, ModraDoc006/r, MEDI4736, Infigratinib, SM-88, PQR309, PF-07248144, MCLA-128, SGN-CD228A, RLY-2608, BLU-222, TT-00420, HMPL-013, Zilovertamab vedotin, DAN-222, Niraparib, G1T38, Poziotinib Hydrochloride, EOC202, XZP-3287, RGT-419B, ASTX727, AND019, Lerociclib, SGN-STNV, SCR-6852, NMS-03305293, TOL2506, ZN-c5, AC682, HS-10342, ZEN003694, Nadunolimab, BLEX 404, Olinvacimab, AL101, eryaspase, EndoTAG-1, PMD-026, Chiauranib, OTS167PO, PVX-410, and others.

Dive deep into rich insights for emerging HER2 negative Breast Cancer Pipeline therapies and assessment, visit @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction
2. Executive Summary
3. HER2 negative Breast Cancer: Overview
4. Pipeline Therapeutics
5. Late Stage Products (Phase III)
5.1. Dato-DXd: Daiichi Sankyo, Inc.
6. Mid Stage Products (Phase II)
6.1. CX-2009: CytomX Therapeutics
7. Early Stage Products (Phase I/II)
7.1. BPI-1178: Beta Pharma (Suzhou) Co., Ltd.
8. Therapeutic Assessment
9. Inactive Products
10. Collaborations Assessment- Licensing / Partnering / Funding
11. HER2 negative Breast Cancer- Unmet Needs
12. HER2 negative Breast Cancer- Market Drivers and Barriers
13. Appendix
14. About DelveInsight

For further information on the HER2 negative Breast Cancer clinical trials and current pipeline therapeutics, reach out @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HER2 negative Breast Cancer Pipeline and Companies Analysis Report (2022): Analysis of Clinical Trials Landscape, Therapies, Route of Administration, Mechanism of Action and Developments | DelveInsight here

News-ID: 2775227 • Views:

More Releases from DelveInsight Business Research

Global Uterine Fibroids Treatment Devices Market is projected by DelveInsight to grow at a CAGR of 8.57% by 2032, states DelveInsight
Global Uterine Fibroids Treatment Devices Market is projected by DelveInsight to …
DelveInsight's latest publication, "Uterine Fibroids Treatment Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive evaluation of the current market status, future opportunities, upcoming technological advancements, key challenges, and major growth determinants. The report also highlights breakthrough products under development and profiles the prominent companies actively shaping the Uterine Fibroids Treatment Devices industry. According to DelveInsight's analysis, the growing prevalence of uterine fibroids particularly among women of reproductive age
Global AI in Remote Patient Monitoring Market Forecasted to Grow at 27.13% CAGR Through 2032, Reports DelveInsight
Global AI in Remote Patient Monitoring Market Forecasted to Grow at 27.13% CAGR …
According to DelveInsight's analysis, North America is expected to dominate the Artificial Intelligence (AI) in Remote Patient Monitoring market from 2025 through 2032. This strong regional performance is attributed to the growing burden of chronic illnesses including cancer well-established healthcare infrastructure, rapid adoption of digital health technologies, and supportive government policies. Additionally, increased investment in digital health and the widespread use of wearables and connected medical devices are significantly accelerating
DelveInsight Strengthens Pharma Decision-Making with Advanced Competitive Intelligence News Monitoring Solutions
DelveInsight Strengthens Pharma Decision-Making with Advanced Competitive Intell …
As the pharmaceutical industry accelerates toward rapid innovation and heightened competition, access to timely, actionable intelligence has become indispensable. DelveInsight, a premier life sciences market research and consulting organization, has launched an enhanced Competitive Intelligence (CI) News Monitoring service designed to equip pharmaceutical companies with real-time insights into clinical, regulatory, and commercial developments. This solution is reshaping how organizations interpret market shifts and make evidence-based strategic decisions. Stay Ahead of the
DelveInsight Releases In-Depth Market & Competitive Intelligence Report on the Global Cell Imaging Technology Landscape to Guide Strategic Commercial Decisions
DelveInsight Releases In-Depth Market & Competitive Intelligence Report on the G …
DelveInsight, a prominent provider of life sciences market research and strategic consulting, has announced the publication of its latest analytical report, "Market & Competitive Assessment: Mapping Commercial Success in the Cell Imaging Technology Domain." This comprehensive study delivers a rigorous, data-driven evaluation of the worldwide market for cell imaging and analysis systems, with a dedicated focus on software-enabled platforms such as High-Content Screening (HCS) instruments, flow cytometers, and cell analyzers.

All 5 Releases


More Releases for HER2

Evolving Market Trends In The HER2-Negative Breast Cancer Industry: Regulatory A …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. What Is the Expected HER2-Negative Breast Cancer Market Size During the Forecast Period? The market size of HER2-negative breast cancer has witnessed robust growth lately. With a projected growth at a compound annual growth rate (CAGR) of 8.1%, the market size will balloon from $16.29 billion in 2024 to reach $17.62 billion
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics. What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period? Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period. Global HER2 Inhibitors Market Scope and Market Size The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis. Although more drug